FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891873864> ?p ?o ?g. }

• W2891873864 endingPage "19" @default.
• W2891873864 startingPage "5" @default.
• W2891873864 abstract "The first clinical trials of the safety and efficacy of interferon-alpha2 (IFN-alpha2) were performed about 30 years ago. Since then, several single-arm studies have convincingly demonstrated that IFN-alpha2 is a highly potent anti-cancer agent in several cancer types but unfortunately not being explored sufficiently due to a high toxicity profile when using non-pegylated IFN-alpha2 or high dosages or due to competitive drugs, that for clinicians at first glance might look more attractive. Within the hematological malignancies, IFN-alpha2 has only recently been revived in patients with the Philadelphia-negative myeloproliferative neoplasms-essential thrombocytosis, polycythemia vera, and myelofibrosis (MPNs)-and in patients with chronic myelogenous leukemia (CML) in combination with tyrosine kinase inhibitors. In this review, we tell the IFN story in MPNs from the very beginning in the 1980s up to 2018 and describe the perspectives for IFN-alpha2 treatment of MPNs in the future. The mechanisms of actions are discussed and the impact of chronic inflammation as the driving force for clonal expansion and disease progression in MPNs is discussed in the context of combination therapies with potent anti-inflammatory agents, such as the JAK1-2 inhibitors (licensed only ruxolitinib) and statins as well. Interferon-alpha2 being the cornerstone treatment in MPNs and having the potential of inducing minimal residual disease (MRD) with normalization of the bone marrow and low-JAK2V617F allele burden, we believe that combination therapy with ruxolitinib may be even more efficacious and hopefully revert disease progression in many more patients to enter the path towards MRD. In patients with advanced and transforming disease towards leukemic transformation or having transformed to acute myeloid leukemia, triple therapy is proposed as a novel treatment modality to be tested in clinical trials combining IFN-alpha2, DNA-hypomethylator, and ruxolitinib. The rationale for this triple therapy is given, including the fact that even in AML, IFN-alpha2 as monotherapy may revert disease progression. We envisage a new and bright future with many more patients with MPNs obtaining MRD on the above therapies. From this stage-and even before-vaccination strategies may open a new horizon with cure being the goal for some patients." @default.
• W2891873864 created "2018-09-27" @default.
• W2891873864 creator A5018937134 @default.
• W2891873864 creator A5053726532 @default.
• W2891873864 date "2018-09-10" @default.
• W2891873864 modified "2023-10-16" @default.
• W2891873864 title "Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?" @default.
• W2891873864 cites W1426432049 @default.
• W2891873864 cites W1495497204 @default.
• W2891873864 cites W1519361392 @default.
• W2891873864 cites W1547986283 @default.
• W2891873864 cites W1609499351 @default.
• W2891873864 cites W1653629301 @default.
• W2891873864 cites W1760182239 @default.
• W2891873864 cites W1781766248 @default.
• W2891873864 cites W1793206271 @default.
• W2891873864 cites W1794615774 @default.
• W2891873864 cites W1853969127 @default.
• W2891873864 cites W1865841947 @default.
• W2891873864 cites W1884746267 @default.
• W2891873864 cites W1897524591 @default.
• W2891873864 cites W1905278501 @default.
• W2891873864 cites W1906130994 @default.
• W2891873864 cites W1906297732 @default.
• W2891873864 cites W1953890763 @default.
• W2891873864 cites W1971113323 @default.
• W2891873864 cites W1971183910 @default.
• W2891873864 cites W1971812559 @default.
• W2891873864 cites W1973499674 @default.
• W2891873864 cites W1974298468 @default.
• W2891873864 cites W1976573435 @default.
• W2891873864 cites W1980568348 @default.
• W2891873864 cites W1985478627 @default.
• W2891873864 cites W1986442976 @default.
• W2891873864 cites W1986492501 @default.
• W2891873864 cites W1986852077 @default.
• W2891873864 cites W1987517009 @default.
• W2891873864 cites W1989567509 @default.
• W2891873864 cites W1992583368 @default.
• W2891873864 cites W1993072636 @default.
• W2891873864 cites W1995162107 @default.
• W2891873864 cites W1997998180 @default.
• W2891873864 cites W1999025699 @default.
• W2891873864 cites W2001645442 @default.
• W2891873864 cites W2003272442 @default.
• W2891873864 cites W2010027180 @default.
• W2891873864 cites W2010075352 @default.
• W2891873864 cites W2010294667 @default.
• W2891873864 cites W2010415591 @default.
• W2891873864 cites W2011059916 @default.
• W2891873864 cites W2015113479 @default.
• W2891873864 cites W2015898229 @default.
• W2891873864 cites W2017153151 @default.
• W2891873864 cites W2017903152 @default.
• W2891873864 cites W2020288960 @default.
• W2891873864 cites W2022687771 @default.
• W2891873864 cites W2024706907 @default.
• W2891873864 cites W2025848587 @default.
• W2891873864 cites W2026413140 @default.
• W2891873864 cites W2027337742 @default.
• W2891873864 cites W2027613124 @default.
• W2891873864 cites W2028078153 @default.
• W2891873864 cites W2028334384 @default.
• W2891873864 cites W2028473680 @default.
• W2891873864 cites W2029529782 @default.
• W2891873864 cites W2030716854 @default.
• W2891873864 cites W2031423498 @default.
• W2891873864 cites W2033856426 @default.
• W2891873864 cites W2034269086 @default.
• W2891873864 cites W2035409103 @default.
• W2891873864 cites W2036363339 @default.
• W2891873864 cites W2037356292 @default.
• W2891873864 cites W2037919426 @default.
• W2891873864 cites W2041191257 @default.
• W2891873864 cites W2042743861 @default.
• W2891873864 cites W2046056065 @default.
• W2891873864 cites W2046830231 @default.
• W2891873864 cites W2048488970 @default.
• W2891873864 cites W2049145190 @default.
• W2891873864 cites W2054940598 @default.
• W2891873864 cites W2057129764 @default.
• W2891873864 cites W2057360098 @default.
• W2891873864 cites W2057650885 @default.
• W2891873864 cites W2058671399 @default.
• W2891873864 cites W2059511422 @default.
• W2891873864 cites W2060394640 @default.
• W2891873864 cites W2060398075 @default.
• W2891873864 cites W2060926084 @default.
• W2891873864 cites W2060968415 @default.
• W2891873864 cites W2063285149 @default.
• W2891873864 cites W2064812526 @default.
• W2891873864 cites W2068884268 @default.
• W2891873864 cites W2071832964 @default.
• W2891873864 cites W2078844752 @default.
• W2891873864 cites W2078972833 @default.
• W2891873864 cites W2083837013 @default.
• W2891873864 cites W2085237060 @default.
• W2891873864 cites W2094200744 @default.

• next